# Foghorn Therapeutics Inc.: financial statements, quarterly

FHTX · Nasdaq · CIK 1822462 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fhtx.md) · [Financials](/companies/fhtx/financials.md) · [Filings](/companies/fhtx/filings.md) · [Insiders](/companies/fhtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fhtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.5](/filings/0001628280-24-045006.md) | [5.8 d](/filings/0001628280-25-010933.md) | [5.1](/filings/0001628280-25-025312.md) | [6.9](/filings/0001628280-25-037606.md) | [7.8](/filings/0001628280-25-049238.md) | [2.9 d](/filings/0001628280-26-016814.md) | [6.0](/filings/0001628280-26-031671.md) | [7.6](/filings/0001628280-26-053819.md) | [8.2](/filings/0001628280-25-049238.md) | [9.2 d](/filings/0001628280-26-016814.md) | [3.3](/filings/0001628280-26-031671.md) | [16.1](/filings/0001628280-26-053819.md) |
| Research and development | $m | [26.3](/filings/0001628280-24-045006.md) | [24.2 d](/filings/0001628280-25-010933.md) | [25.5](/filings/0001628280-25-025312.md) | [23.8](/filings/0001628280-25-037606.md) | [24.7](/filings/0001628280-25-049238.md) | [20.5 d](/filings/0001628280-26-016814.md) | [21.6](/filings/0001628280-26-031671.md) | [21.8](/filings/0001628280-26-053819.md) | [20.0](/filings/0001628280-25-049238.md) | [22.0 d](/filings/0001628280-26-016814.md) | [18.3](/filings/0001628280-26-031671.md) | [18.5](/filings/0001628280-26-053819.md) |
| Operating income | $m | [(17.1)](/filings/0001628280-24-045006.md) | [(25.5) d](/filings/0001628280-25-010933.md) | [(28.2)](/filings/0001628280-25-025312.md) | [(26.6)](/filings/0001628280-25-037606.md) | [(23.9)](/filings/0001628280-25-049238.md) | [(24.0) d](/filings/0001628280-26-016814.md) | [(22.9)](/filings/0001628280-26-031671.md) | [(21.1)](/filings/0001628280-26-053819.md) | [(18.5)](/filings/0001628280-25-049238.md) | [(23.9) d](/filings/0001628280-26-016814.md) | [(21.6)](/filings/0001628280-26-031671.md) | [(8.8)](/filings/0001628280-26-053819.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.7](/filings/0001628280-24-045006.md) | [2.0 d](/filings/0001628280-25-010933.md) | [0.0](/filings/0001628280-24-020455.md) | [0.0](/filings/0001628280-24-035867.md) | [0.0](/filings/0001628280-24-045006.md) | [0.0 d](/filings/0001628280-25-010933.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(14.3)](/filings/0001628280-24-045006.md) | [(24.1) d](/filings/0001628280-25-010933.md) | [(25.0)](/filings/0001628280-25-049238.md) | [(23.0)](/filings/0001628280-25-049238.md) | [(19.1)](/filings/0001628280-25-049238.md) | [(19.5) d](/filings/0001628280-26-016814.md) | [(18.8)](/filings/0001628280-26-053819.md) | [(17.9)](/filings/0001628280-26-053819.md) | [(15.8)](/filings/0001628280-25-049238.md) | [(21.7) d](/filings/0001628280-26-016814.md) | [(19.9)](/filings/0001628280-26-053819.md) | [(7.2)](/filings/0001628280-26-053819.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0001628280-24-045006.md) | not reported | [(0.59)](/filings/0001628280-25-025312.md) | [(0.45)](/filings/0001628280-25-037606.md) | [(0.31)](/filings/0001628280-25-049238.md) | not reported | [(0.30)](/filings/0001628280-26-031671.md) | [(0.28)](/filings/0001628280-26-053819.md) | [(0.25)](/filings/0001628280-25-049238.md) | not reported | [(0.29)](/filings/0001628280-26-031671.md) | [(0.10)](/filings/0001628280-26-053819.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0001628280-24-045006.md) | not reported | [(0.59)](/filings/0001628280-25-025312.md) | [(0.45)](/filings/0001628280-25-037606.md) | [(0.31)](/filings/0001628280-25-049238.md) | not reported | [(0.30)](/filings/0001628280-26-031671.md) | [(0.28)](/filings/0001628280-26-053819.md) | [(0.25)](/filings/0001628280-25-049238.md) | not reported | [(0.29)](/filings/0001628280-26-031671.md) | [(0.10)](/filings/0001628280-26-053819.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [70.3](/filings/0001628280-24-045006.md) | [80.3](/filings/0001628280-25-010933.md) | [79.3](/filings/0001628280-25-025312.md) | [139](/filings/0001628280-25-037606.md) | [57.7](/filings/0001628280-25-049238.md) | [55.5](/filings/0001628280-26-016814.md) | [61.0](/filings/0001628280-26-031671.md) | [72.6](/filings/0001628280-26-053819.md) | [89.3](/filings/0001628280-25-049238.md) | [80.9](/filings/0001628280-26-053819.md) | [87.7](/filings/0001628280-26-031671.md) | [68.1](/filings/0001628280-26-053819.md) |
| Current assets | $m | [265](/filings/0001628280-23-036187.md) | [240](/filings/0001628280-25-010933.md) | [212](/filings/0001628280-24-020455.md) | [290](/filings/0001628280-24-035867.md) | [271](/filings/0001628280-24-045006.md) | [250](/filings/0001628280-26-016814.md) | [225](/filings/0001628280-25-025312.md) | [204](/filings/0001628280-25-037606.md) | [184](/filings/0001628280-25-049238.md) | [163](/filings/0001628280-26-053819.md) | [188](/filings/0001628280-26-031671.md) | [170](/filings/0001628280-26-053819.md) |
| Total assets | $m | [313](/filings/0001628280-23-036187.md) | [286](/filings/0001628280-25-010933.md) | [255](/filings/0001628280-24-020455.md) | [329](/filings/0001628280-24-035867.md) | [308](/filings/0001628280-24-045006.md) | [284](/filings/0001628280-26-016814.md) | [259](/filings/0001628280-25-025312.md) | [226](/filings/0001628280-25-037606.md) | [205](/filings/0001628280-25-049238.md) | [198](/filings/0001628280-26-053819.md) | [222](/filings/0001628280-26-031671.md) | [203](/filings/0001628280-26-053819.md) |
| Current liabilities | $m | [52.0](/filings/0001628280-23-036187.md) | [58.4](/filings/0001628280-25-010933.md) | [52.1](/filings/0001628280-24-020455.md) | [50.9](/filings/0001628280-24-035867.md) | [56.8](/filings/0001628280-24-045006.md) | [67.0](/filings/0001628280-26-016814.md) | [71.3](/filings/0001628280-25-025312.md) | [77.8](/filings/0001628280-25-037606.md) | [85.1](/filings/0001628280-25-049238.md) | [59.7](/filings/0001628280-26-053819.md) | [64.4](/filings/0001628280-26-031671.md) | [50.6](/filings/0001628280-26-053819.md) |
| Total liabilities | $m | [371](/filings/0001628280-23-036187.md) | [363](/filings/0001628280-25-010933.md) | [352](/filings/0001628280-24-020455.md) | [343](/filings/0001628280-24-035867.md) | [337](/filings/0001628280-24-045006.md) | [330](/filings/0001628280-26-016814.md) | [320](/filings/0001628280-25-025312.md) | [303](/filings/0001628280-25-037606.md) | [295](/filings/0001628280-25-049238.md) | [307](/filings/0001628280-26-053819.md) | [299](/filings/0001628280-26-031671.md) | [284](/filings/0001628280-26-053819.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(57.4)](/filings/0001628280-24-045006.md) | [(77.2)](/filings/0001628280-26-016814.md) | [(97.5)](/filings/0001628280-25-049238.md) | [(14.3)](/filings/0001628280-25-049238.md) | [(28.3)](/filings/0001628280-25-049238.md) | [(45.5)](/filings/0001628280-26-053819.md) | [(61.7)](/filings/0001628280-26-053819.md) | [(76.7)](/filings/0001628280-26-053819.md) | [(89.7)](/filings/0001628280-25-049238.md) | [(109)](/filings/0001628280-26-053819.md) | [(76.4)](/filings/0001628280-26-053819.md) | [(81.0)](/filings/0001628280-26-053819.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(27.2) d](/filings/0001628280-24-045006.md) | [(27.5) d](/filings/0001628280-25-010933.md) | [(29.3)](/filings/0001628280-25-025312.md) | [(25.5) d](/filings/0001628280-25-037606.md) | [(21.0) d](/filings/0001628280-25-049238.md) | [(24.5) d](/filings/0001628280-26-016814.md) | [(24.0)](/filings/0001628280-26-031671.md) | [(21.0) d](/filings/0001628280-26-053819.md) | [(18.9) d](/filings/0001628280-25-049238.md) | [(22.3) d](/filings/0001628280-26-016814.md) | [(25.3)](/filings/0001628280-26-031671.md) | [(17.8) d](/filings/0001628280-26-053819.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001628280-24-045006.md) | [0.0 d](/filings/0001628280-25-010933.md) | [0.1](/filings/0001628280-25-025312.md) | [0.0 d](/filings/0001628280-25-037606.md) | [0.3 d](/filings/0001628280-25-049238.md) | [0.5 d](/filings/0001628280-26-016814.md) | [0.0](/filings/0001628280-26-031671.md) | [0.0 d](/filings/0001628280-26-053819.md) | [0.0 d](/filings/0001628280-25-049238.md) | [0.0 d](/filings/0001628280-26-016814.md) | [0.0](/filings/0001628280-26-031671.md) | [0.1 d](/filings/0001628280-26-053819.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.7](/filings/0001628280-23-036187.md) | [41.8](/filings/0001628280-24-020455.md) | [41.8](/filings/0001628280-24-035867.md) | [42.0](/filings/0001628280-24-045006.md) | [42.4](/filings/0001628280-25-025312.md) | [51.6](/filings/0001628280-25-037606.md) | [62.6](/filings/0001628280-25-049238.md) | [62.8](/filings/0001628280-26-031671.md) | [63.0](/filings/0001628280-26-053819.md) | [63.0](/filings/0001628280-25-049238.md) | [69.5](/filings/0001628280-26-031671.md) | [70.6](/filings/0001628280-26-053819.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,385,315 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-053819.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.